Neuroscience News and Research

RSS

First neurobiological model for third-party punishment

In a paper published online on April 15 by the journal Nature Neuroscience, a pair of neuroscientists from Vanderbilt and Harvard universities has proposed the first neurobiological model for third-party punishment. It outlines a collection of potential cognitive and brain processes that evolutionary pressures could have re-purposed to make this behavior possible.

19 Apr 2012

Brain size and IQ secret may lie in genes: Study

The study, conducted by a team of more than 200 scientists from 100 institutions worldwide, measured the size of the brain and its memory centers in thousands of MRI images from 21,151 healthy people while simultaneously screening their DNA. According to the researchers, a variant in a gene called HMGA2 affected the brain size, as well as a person's intelligence.

18 Apr 2012

Blood test to diagnose depression in adolescents

Researchers have developed a blood test that can diagnose depression in teens, a step they hope will lead to a better way to identify the disorder in young people. At present diagnosing depression depends entirely on a patient's willingness to report symptoms. For teens, the diagnosis is particularly challenging, given the natural emotional ups and downs of adolescence.

18 Apr 2012

Abbott reports positive results from LCIG Phase 3 trial for advanced Parkinson's disease

Abbott announced today the results from a Phase 3 trial evaluating the company's investigational compound for advanced Parkinson's disease, levodopa-carbidopa intestinal gel (LCIG).

18 Apr 2012

Levodopa-carbidopa intestinal gel better than standard oral form to treat advanced Parkinson's disease

A levodopa-carbidopa intestinal gel (LCIG) works better than standard oral levodopa-carbidopa in reducing "off" time in patients with advanced Parkinson's disease.

18 Apr 2012

SBRT shortens radiation treatment time for gynecologic cancers

About 71,500 women in the United States are diagnosed with a gynecologic cancer every year, according to the Centers for Disease Control. Researchers from University Hospitals Case Medical Center have developed a more effective way to treat gynecologic cancers, shortening radiation treatment time from five weeks to three days. The method will be published in the Journal of Visualized Experiments (JoVE) on April 17.

18 Apr 2012

Tumor microenvironment contributes critically to drug response

It should be possible to significantly improve the response of common cancers to existing "classical" chemotherapy drugs, say scientists at Cold Spring Harbor Laboratory (CSHL), by introducing agents that alter the interaction of cancer cells with their immediate surroundings, called the tumor microenvironment.

17 Apr 2012

Study finds lower cytokine levels in the plasma of children with autism

A University of Kansas Medical Center study found significantly lower levels of several cytokines, the immune system's messengers and regulators, in the plasma of children with autism disorder (AD) compared to that of unrelated healthy siblings from other families who had members with autism spectrum disorders.

17 Apr 2012

ONO-4641 reduces number of lesions in people with MS

An investigational oral drug called ONO-4641 reduced the number of lesions in people with multiple sclerosis (MS), according to the results of a phase two clinical trial to be presented as Emerging Science at the American Academy of Neurology's 64th Annual Meeting in New Orleans April 21 to April 28, 2012.

17 Apr 2012

Steroids still work better for patients with sciatica

Despite the great promise that injecting a new type of anti-inflammatory pain medicine into the spine could relieve the severe leg and lower back pain of sciatica, a Johns Hopkins-led study has found that the current standard of care with steroid injections still does better.

17 Apr 2012

Morphotek commences MORAb-004 Phase II study in metastatic colorectal cancer

Morphotek, Inc., a subsidiary of Eisai Inc., announced today that it has commenced a multi-center, Phase II study evaluating the safety and efficacy of MORAb-004 in the treatment of metastatic colorectal cancer that is refractory to all standard therapy.

17 Apr 2012

Conformetrix's NMR-based technology to be applied across AstraZeneca's pre-clinical therapeutic pipeline

Conformetrix Ltd, a leader in optimising drug discovery and design, and AstraZeneca announced today that they have signed a research collaboration agreement under which Conformetrix's proprietary NMR-based technology will be applied across AstraZeneca's pre-clinical therapeutic pipeline to enhance lead discovery and hit identification.

16 Apr 2012

New drug to detect beta-amyloid plaques may help diagnose AD earlier

Use of a new drug to detect the beta-amyloid plaques in the brain that are hallmark signs of Alzheimer's disease may help doctors diagnose the disease earlier, according to research that will be presented as part of the Emerging Science program (formerly known as Late-Breaking Science) at the American Academy of Neurology's 64th Annual Meeting in New Orleans April 21 to April 28, 2012.

16 Apr 2012

Intelligence may have co-evolved with worry in humans

Worrying may have evolved along with intelligence as a beneficial trait, according to a recent study by scientists at SUNY Downstate Medical Center and other institutions.

16 Apr 2012

TJUH opens new treatment center for Barrett's esophagus

Thomas Jefferson University Hospital announces the opening of its new Jefferson Barrett's Esophagus Treatment Center, one of only a few dedicated Barrett's centers in the country and the first multidisciplinary center solely dedicated to treating Barrett's esophagus disease in Philadelphia.

16 Apr 2012

New genes may explain individual differences in brain size and intelligence

In the world's largest brain study to date, a team of more than 200 scientists from 100 institutions worldwide collaborated to map the human genes that boost or sabotage the brain's resistance to a variety of mental illnesses and Alzheimer's disease.

16 Apr 2012

DNDi, AstraZeneca enter collaboration on drug-compound screening for NTDs

AstraZeneca and the Drugs for Neglected Diseases initiative (DNDi) today announce an agreement to collaborate on drug-compound screening for leishmaniasis, Chagas disease, and sleeping sickness, three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.

12 Apr 2012

Newer antidepressant decreases depression in Parkinson's patients without worsening motor problems

Certain antidepressants appear to decrease depression in people with Parkinson's disease without worsening motor problems, according to a study published in the April 11, 2012, online issue of Neurology, the medical journal of the American Academy of Neurology.

12 Apr 2012

AstraZeneca introduces DUTOPROL for hypertension

AstraZeneca today announced the availability of DUTOPROL (metoprolol succinate extended release/hydrochlorothiazide) Tablets, the first and only once-daily antihypertensive agent that contains the active ingredient of TOPROL-XL (metoprolol succinate) plus a low-dose diuretic that provides proven blood pressure lowering at 24 hours.

12 Apr 2012

Abnormally low level of SMN protein linked to movement problems in spinal muscular atrophy

An abnormally low level of a protein in certain nerve cells is linked to movement problems that characterize the deadly childhood disorder spinal muscular atrophy, new research in animals suggests.

12 Apr 2012